Recombinant human IL-4 protein - Bioactive cytokine

Recombinant cytokine, source: E. coli

ABOUT

Human IL-4 protein - E. coli -expressed, tag-free, with HSA

Recombinant human IL-4 is a high-quality and biologically active cytokine, validated using proprietary IL-4/IL-13 reporter cells. This member of the IL-2/γc superfamily is produced in E. coli and thoroughly purified to remove endotoxins.

Recombinant human IL-4 can be used together with HEK-Blue™ IL-4/IL-13 cells for the screening of inhibitory molecules, such as Dupilumab, a therapeutic monoclonal antibody targeting the IL-4Rα subunit of the IL-4 receptor (see figures).

 

Key features

  • Each lot is validated using HEK-Blue™ IL-4/IL-13 cells
  • Endotoxin < 0.1 EU/µg
  • 0.2 µm sterile-filtered

Applications

  • Standard for IL-4 detection and quantification assays
  • Screening and release assays for antibodies blocking IL-4 signaling
  • Screening and release assays for engineered IL-4

 

Interleukin 4 (IL-4) shares a common receptor subunit, IL-4Rα, with IL-13. These two cytokines play an important role in anti-parasitic immune responses. Dysregulated IL-4 /IL-13 expression contributes to Th2-mediated diseases, including asthma and atopic dermatitis.

more details More details

All InvivoGen products are for internal research use only, and not for human or veterinary use.

SPECIFICATIONS

Specifications

Source
E. coli
Synonyms
B-cell stimulatory factor 1
Lymphocyte stimulatory factor 1
Accession sequence

P05112

Molecular weight
~ 15 kDa (SDS-PAGE)
Purity
≥98% (SDS-PAGE)
Solubility

100 μg/ml in water

Formulation buffer

Phosphate buffer saline (pH 7.4), 5% saccharose, 2% HSA

Tested applications

Cellular assays

Quality control

Each lot is functionally tested and validated.

CONTENTS

Contents

  • Product: 
    Recombinant human IL-4
  • Cat code: 
    rcyec-hil4
  • Quantity: 
    10 µg
Includes:

1.5 ml endotoxin-free water.

Shipping & Storage

  • Shipping method:  Room temperature
  • Storage:

    • -20°C

    Caution:

    • Avoid repeated freeze-thaw cycles

Details

IL-4 background

IL-4, also known as B-cell stimulatory factor 1 or Lymphocyte stimulatory factor 1, is a cytokine that belongs to the IL-2/γc superfamily. IL-4 is produced as a secreted monomeric molecule by activated CD4+ T cells, Natural Killer T cells (NKT cells), group 2 innate lymphoid cells (ILC2s), macrophages, mast cells, basophils, or eosinophils [1].

IL-4 binds two types of heterodimeric receptors and exerts pleiotropic actions on multiple cell lineages. Type I receptors are composed of the IL-4Rα and the common γ chains. Type II receptors are composed of the IL-4Rα and IL-13Rα1 chains. The binding of IL-4 to its receptors triggers a signaling cascade leading to the activation of STAT6. Subsequent gene expression drives Th2 and Th9 helper cell differentiation and M2 macrophage polarization. In B cells, IL-4 promotes proliferation and IgE immunoglobulin class switching [1, 2]. In non-hematopoietic cells, the functions of IL-4 span from mucus hypersecretion in airway epithelial cells, extracellular matrix protein deposition by fibroblasts, and growth of endothelial cells [1]. Altogether, the downstream IL-4 effector functions participate in parasitic infection clearance and allergic reactions [2].

 

Relevance for therapeutics development

IL-4 is a key cytokine for controlling infections by extracellular parasites. However, along with IL-13, it also contributes to harmful allergic responses [2, 3]. As the prevalence of chronic allergic diseases such as asthma and atopic dermatitis is increasing worldwide, there has been a keen interest in the therapeutic blocking of IL-4 and IL-13 signaling.

Dupilumab is a fully human monoclonal antibody (mAb) that targets the IL-4Rα subunit [4]. It acts like a receptor antagonist and inhibits the signaling of both IL-4 and IL-13 [4]. Dupilimab was FDA-approved in 2017 for treating asthma, atopic dermatitis, and chronic sinusitis [4, 5]. Due to its favorable safety profile and established clinical use, Dupilumab holds significant promise for amending treatment options for many dermatologic conditions [6].

The development of engineered IL-4 cytokines has also been explored. For example, IL-4 "superkines" featuring a higher affinity for type I or type II receptors have been generated to target cells expressing lower second chain (γc or IL-13Rα1) numbers. To go further, engineered super-IL-4 fused to Pseudomonas toxin has been tested for targeted toxin delivery in tumor cells expressing IL-4 receptors [7].

 

References:

1. Keegan, A.D., et al., 2021. Recent advances in understanding the role of IL-4 signaling. Fac Rev. 10: 71.
2. Bernstein, Z.J., et al., 2023. Engineering the IL-4/IL-13 axis for targeted immune modulation. Immunol Rev. 320(1):29-57. 
3. Ogulur, I., et al., 2025. Type 2 immunity in allergic diseases. Cell & Mol Immunol, 22(3):211-242.
4. Harb, H. & Chatila, T.A., 2020. Mechanisms of Dupilumab. Clin Exp Allergy. 50(1):5-14.
5. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761055s040lbl.pdf
6. Olbrich, H., et al., 2023. Dupilumab in Inflammatory Skin Diseases: A Systematic Review. Biomolecules.13(4):634.
7. Leonard, W.J & Lin, J.X, 2023. Strategies to therapeutically modulate cytokine action. Nat Rev Drug Discov. 22(10):827-854.

DOCUMENTS

Documents

Recombinant human IL-4

Technical Data Sheet

Validation Data Sheet

Safety Data Sheet

Certificate of analysis

Need a CoA ?

CUSTOMER SERVICE & TECHNICAL SUPPORT

Question about this product ?